Author

Erica J. Young

Scripps Research Institute

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1 Neuroscience· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Assay:imaging· 1

Frequent Co-Authors

Courtney A. MilleriD· 4 shared Gavin RumbaughiD· 3 shared Theodore M. KameneckaiD· 3 shared Katalin TóthiD· 2 shared László RadnaiiD· 2 shared Michael D. CameroniD· 2 shared Patrick R. GriffiniD· 2 shared Aagam Patel· 1 shared

Activity by Year

2020-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 36 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

Courtney A. MillerORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Early overactivation of non-muscle myosin II during adaptation to combined BRAF and MEK inhibitors in dedifferentiating cutaneous melanomas

Andrea Garcia-Perez, Lucía Sanchez-Garcia, Marta Duran-Renieblas, Federica Sella, Silvia Novo-Acedo, Angel Delgado-Lopez, Adrian Barreno, Judith Gracia, Christopher Rios, Erica J. Young, Laszlo Radnai, Clara Diaz-Utrilla, Julia M. Martinez-Gomez, Rosa M. Marti, Marta C. Sallan, , José Luis Orgaz

This study shows that non-muscle myosin II overactivation occurs in dedifferentiating melanomas adapting to BRAF and MEK inhibitors, and targeting NMII with BMi reduces drug-tolerant persister cell survival.

bioRxiv · Dec 3, 2025 · PreprintCancer Biology

MT-125 Inhibits Non-Muscle Myosin IIA and IIB, Synergizes with Oncogenic Kinase Inhibitors, and Prolongs Survival in Glioblastoma

Rajappa S. Kenchappa, László Radnai, Erica J. Young, Natanael Zarco, Li Lin, Athanassios Dovas, Christian T. Meyer, Ashley N. Haddock, Alice Hall, Katalin Tóth, Peter Canoll, Naveen K H Nagaiah, Gavin Rumbaugh, Michael D. Cameron, Theodore M. Kamenecka, , Steven S. Rosenfeld

Cell · Jun 10, 2025Peer-reviewedCancer Biology

Development of Clinically Viable Non-Muscle Myosin II Small Molecule Inhibitors with Broad Therapeutic Potential

László Radnai, Erica J. Young, Carlos Massayuki Kikuti, Katalin Tóth, Minghai Zhou, Madalyn Hafenbreidel, Rebecca F. Stremel, Lin Li, Paolo Pasetto, Xiaomin Jin, Aagam Patel, Michael P. Conlon, Sherri B. Briggs, Leïla Heidsieck, Hugh Lee Sweeney, , Courtney A. Miller

This paper develops a selective non-muscle myosin II inhibitor, MT-228, with high brain penetration and efficacy in preclinical models, offering therapeutic potential for diseases like stimulant use disorder.

Cell · Oct 7, 2024Peer-reviewedCell Biology

Methamphetamine learning induces persistent nonmuscle myosin II-dependent spine motility in the basolateral amygdala

Erica J. Young, Lin Hua, Theodore M. Kamenecka, Gavin Rumbaugh, Courtney A. Miller

The paper shows that METH learning causes long-lasting NMII-dependent spine motility in BLA neurons, which can be reversed by NMII inhibition.

Journal of Neuroscience · Feb 17, 2020Peer-reviewedNeuroscience